This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

ibalizumab (Trogarzo®)

Reference No. 3375

Publication date:

Appraisal information

ibalizumab (Trogarzo®) 200 mg concentrate for solution for infusion
ibalizumab (Trogarzo®) Unspecified
ibalizumab (Trogarzo®) Unspecified

Company: Theratechnologies Inc
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/06/2020

Current Progress

Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, ibalizumab (Trogarzo®) cannot be endorsed for use within NHS Wales for use in combination with other antiretroviral(s) for the treatment of adults infected with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen
Statement of Advice (SOA)